BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29899991)

  • 1. Prolonged diabetic ketoacidosis associated with canagliflozin.
    Sloan G; Kakoudaki T; Ranjan N
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29899991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin-associated diabetic ketoacidosis: a case report.
    Chai PR; Bonney C; Blohm E; Boyer EW; Babu KM
    Toxicol Commun; 2017; 1(1):2-5. PubMed ID: 29978156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
    He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
    Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
    Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
    J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
    Diaz-Ramos A; Eilbert W; Marquez D
    Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
    Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
    Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
    Ahmed M; McKenna MJ; Crowley RK
    Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
    Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
    Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
    Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
    Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
    Chauhan S; Manov A; Dhillon GS; Shah P
    Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic diabetic ketoacidosis caused by canagliflozin: a case report.
    Fukuda M; Nabeta M; Muta T; Fukami K; Takasu O
    Int J Emerg Med; 2020 Jan; 13(1):2. PubMed ID: 31969112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late-Onset Euglycemic Diabetic Ketoacidosis in a Patient With Massive Stroke Requiring Decompressive Craniectomy: A Case Report.
    Hussaini SA; Aziz A; Musa M; Alamin M; Danjuma M
    Cureus; 2021 Oct; 13(10):e18629. PubMed ID: 34765377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapy.
    Westcott GP; Segal AR; Mitri J; Brown FM
    Endocrinol Diabetes Metab; 2020 Apr; 3(2):e00117. PubMed ID: 32318635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin.
    Candelario N; Wykretowicz J
    Oxf Med Case Reports; 2016 Jul; 2016(7):144-6. PubMed ID: 27471597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normoglycemic diabetic ketoacidosis in a type 2 diabetes patient on dapagliflozin: A case report.
    Matli VVK; Fariduddin MM; Asafo-Agyei KO; Bansal N
    Clin Case Rep; 2021 Dec; 9(12):e05144. PubMed ID: 34917366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.